Patterns of Medication in Early Pregnancy: A Preliminary Report from the Jerusalem Perinatal Study

Harlap, Susan; Davies, A.M.; Haber, M. Kempf; Prywes, R; Rossman, Hava; Samueloff, Naomi

doi:10.1007/978-1-4684-3219-0_42

Advances in Experimental Medicine and Biology

1972

DOI: 10.1007/978-1-4684-3219-0_42

|View full text |Cite

Patterns of Medication in Early Pregnancy: A Preliminary Report from the Jerusalem Perinatal Study

Susan Harlap¹,

A.M. Davies²,

M. Kempf Haber³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1981

1990

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Health, growth and sexual development of teenagers exposed in utero to medroxyprogesterone acetate

Jaffe¹,

Shye²,

Harlap³

et al. 1990

Paediatric Perinatal Epid

View full text Add to dashboard Cite

General health, growth and sexual development were evaluated in 74 teenage boys and 98 girls who had been exposed to medroxyprogesterone acetate (MPA) in utero, and 385 boys and 448 girls not exposed. In this 17-year prospective study, the ascertainment of the end points was 'double blind' in that neither the interviewer nor the subject was aware of our interest in MPA. On average, girls exposed to MPA reported reaching the menarche 4 months earlier than the comparison group. This difference disappeared, however, in a multiple regression analysis taking into account social class, the mother's age at menarche and height of the girl's mother and father. Boys exposed to MPA reported their growth spurt to have occurred an average of 6 months earlier and voices to have broken 5 months earlier than unexposed boys. Again, the differences between them and the comparison group disappeared after controlling for confounding variables. There were no significant differences between the MPA-exposed and comparison groups in a wide variety of indices of health reported by the teenagers' mothers. These findings are consistent with the hypothesis that intrauterine exposure to MPA, in the doses used for pregnancy maintenance or for contraception, poses no threat to the long-term health and development of the progeny.

show abstract

Health, growth and sexual development of teenagers exposed in utero to medroxyprogesterone acetate

Jaffe¹,

Shye²,

Harlap³

et al. 1990

Paediatric Perinatal Epid

View full text Add to dashboard Cite

show abstract

Teratogenesis: A Review of the Basic Principles with a Discussion of Selected Agents: Part II

Hays

1981

Drug Intelligence & Clinical Pharmacy

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Patterns of Medication in Early Pregnancy: A Preliminary Report from the Jerusalem Perinatal Study

Cited by 2 publications

References 0 publications

Health, growth and sexual development of teenagers exposed in utero to medroxyprogesterone acetate

Health, growth and sexual development of teenagers exposed in utero to medroxyprogesterone acetate

Teratogenesis: A Review of the Basic Principles with a Discussion of Selected Agents: Part II

Contact Info

Product

Resources

About